Introduction Attention-deficit/hyperactivity disorder (ADHD) affects millions worldwide, requiring careful management through stimulant medications such as Adderall (mixed amphetamine salts) and Ritalin (Methylphenidate). While highly effective in improving focus, attention, and behavioral control, these medications carry risk profiles, potential interactions, and regulatory restrictions, particularly in the UK and EU. In addition to prescription medications, there is […]